EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Stridor Is an Independent Risk Factor for Mortality and Disease Progression in Patients with Multiple System Atrophy

Pauline Dodet iD, Cecile Proust-Lima, Federico Sirna, David Bendetowicz, Giulia Lazzeri, Rachel Debs, Anna Delamarre, Margaux Dunoyer, Margherita Fabbri iD, Claire Georges iD, Imad Ghorayeb, David Grabli und 7 weitere

Movement Disorders · 2026-01 · 41 (1) · 120-128

DOI: 10.1002/mds.70080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Movement Disorders, online erschienen am 07.10.2025. Verfasst von Pauline Dodet und 18 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne Université, Paris Brain Institute, Inserm, CNRS, Paris, France. Hauptthemen laut MEDLINE: Multiple System Atrophy, Respiratory Sounds, Sleep Apnea Syndromes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aim Stridor and sleep apnea syndrome (SAS) are common in multiple system atrophy (MSA). Retrospective cohort studies have yielded conflicting results regarding the consequences of stridor and SAS on the disease course. This study aimed to assess the prognostic significance of stridor and SAS, as well as the potential survival benefits of continuous positive airway pressure (CPAP) therapy.

Method

Retrospective data from 232 participants with MSA (mean age 65 years old, 51% male) from the three sites of the French Reference Center for MSA were analyzed. Patients underwent video‐polysomnography to confirm the presence of stridor and SAS (AHI >15). Survival analyses adjusted for disease progression, age, sex, MSA subtype, and time since symptom onset were conducted using a joint modeling approach. Disease progression was quantified by the repeated assessments of a six‐item composite score and the total Unified MSA Rating Scale I + II.

Results

Stridor was independently associated with an increased risk of mortality (hazard ratio [HR] = 2.44 [1.41;4.22]), even after adjusting for disease progression. Stridor was also linked to more severe disease progression over time. In contrast, SAS did not independently predict mortality or disease progression. CPAP therapy initiation was associated with a substantial reduction in mortality risk after adjusting for center and AHI (HR = 0.40 [0.19;0.85], P = 0.017).

Discussion

Stridor is a critical prognostic factor in MSA, associated with higher mortality and worse disease progression, whereas SAS alone is not associated with a change in mortality. Patients undergoing CPAP therapy have a much better survival among those with stridor. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple System AtrophyRespiratory SoundsSleep Apnea SyndromesHumansMaleFemaleAgedDisease ProgressionRetrospective StudiesRisk FactorsMiddle AgedContinuous Positive Airway PressurePolysomnographyPrognosis

Stichwörter der Autor:innen

multiple system atrophysleepstridor

Autor:innen und Institutionen

  • Sorbonne Université, Paris Brain Institute, Inserm, CNRS, Paris, France.
  • Sleep Unit, National Reference Centre for Orphan Diseases, Narcolepsy and Rare Hypersomnias, Pitié-Salpêtrière hospital, AP-HP, Paris, France.
  • Inserm, Bordeaux Population Health Research Center, U1219, University of Bordeaux, Bordeaux, France.
  • CIC1401-EC, Inserm, Bordeaux, France.
  • CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives, IMNc, CRMR AMS, NS-Park/FCRIN Network, Toulouse, France.
  • CNRS, IMN UMR 5293, University of Bordeaux, Bordeaux, France.

ORCID-Profile: Pauline Dodet, Margherita Fabbri, Claire Georges, Olivier Rascol, Isabelle Arnulf

Zitieren

APA

Dodet, P., Proust-Lima, C., Sirna, F., Bendetowicz, D., Lazzeri, G., Debs, R., Delamarre, A., Dunoyer, M., Fabbri, M., Georges, C., Ghorayeb, I., Grabli, D., Londner, C., Traon, A. P., Patout, M., Rascol, O., Arnulf, I., Foubert-Samier, A., & Meissner, W. G. (2026). Stridor Is an Independent Risk Factor for Mortality and Disease Progression in Patients with Multiple System Atrophy. Movement Disorders, 41(1), 120-128. https://doi.org/10.1002/mds.70080

Vancouver

Dodet P, Proust-Lima C, Sirna F, Bendetowicz D, Lazzeri G, Debs R, et al. Stridor Is an Independent Risk Factor for Mortality and Disease Progression in Patients with Multiple System Atrophy. Movement Disorders. 2026;41(1):120-128. doi:10.1002/mds.70080

BibTeX
@article{Dodet2026,
  author = {Dodet, Pauline and Proust-Lima, Cecile and Sirna, Federico and Bendetowicz, David and Lazzeri, Giulia and Debs, Rachel and Delamarre, Anna and Dunoyer, Margaux and Fabbri, Margherita and Georges, Claire and Ghorayeb, Imad and Grabli, David and Londner, Cécile and Traon, Anne Pavy-Le and Patout, Maxime and Rascol, Olivier and Arnulf, Isabelle and Foubert-Samier, Alexandra and Meissner, Wassilios G},
  title = {Stridor Is an Independent Risk Factor for Mortality and Disease Progression in Patients with Multiple System Atrophy},
  journal = {Movement Disorders},
  year = {2026},
  volume = {41},
  number = {1},
  pages = {120--128},
  doi = {10.1002/mds.70080}
}
Kostenlos starten →